We are investigating the fairness of the price of $335.00 per share in cash for which Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) has agreed to be sold to Johnson & Johnson. The sales price is below the price target for Shockwave of at least one Wall Street analyst (source: TipRanks).
If you remain a Shockwave shareholder and question the fairness of the price, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.
Why is there an investigation?
On April 5, 2024, Shockwave announced that it had agreed to be sold to Johnson & Johnson for $335.00 per share in cash.
“We are investigating whether the Shockwave Board of Directors acted in the best interests of Shockwave shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the price agreed upon is fair to Shockwave shareholders, as well as whether all material information regarding the transaction has been fully disclosed.”
Notably, according to TipRanks, the sales price is below the price target of $368.00 per share of Kristen Stewart at C.L. King set on March 27, 2024.